State Library opens new interactive learning lab for children
The lab is part of a series of programs organized by the state librarian aimed at benefiting the community. It provides an interactive environment where children can engage with reading and learning through modern technology.
Lieutenant Governor Billy Nungesser praised the initiative, stating that it is making a significant difference in the community.
The literacy and learning lab is designed to foster a love of reading among children by providing them with engaging and interactive experiences. These activities are intended to make reading fun and accessible, encouraging children to explore and learn.
This initiative is one of many efforts by the state librarian to enhance educational opportunities within the community. By incorporating technology into learning, the program aims to meet the needs of today's digital-savvy youth.
The opening of the literacy and learning lab marks a positive step towards improving educational resources for children in the community, supported by local leaders like Lieutenant Governor Nungesser.
Latest News
Construction of multi-million dollar LSUS bridge is underway
State Library opens new interactive learning lab for children
LSU Board of Supervisors initiates presidential search
Years after abuse reports, ex-coach at renowned US gymnastics academy is arrested by FBI
EPA emails show agency tried to discredit independent scientist
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company's open-label extension study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The extension study (NCT06961344) is evaluating the long-term safety and tolerability of zagociguat in individuals with MELAS who complete treatment in the global Phase 2b PRIZM study, which is expected to complete screening in the next months. The extension study is intended to provide uninterrupted access to zagociguat for clinical trial participants for up to two years and evaluate the long-term safety of zagociguat. 'We're pleased to reach the important milestone of enrolling the first PRIZM study participant into our open-label extension study,' said Peter Hecht, Ph.D., chief executive officer of Tisento. 'Enthusiastic engagement by MELAS patients and physicians is powering momentum in our development program, and we look forward to completing PRIZM enrollment in the next few months.' The PRIZM study is actively enrolling in the U.S., Canada, Australia, United Kingdom, Italy, and Germany, and interested individuals are encouraged to discuss participation with their physician. PRIZM is evaluating the impact of zagociguat treatment on fatigue, cognitive performance, and other key aspects of MELAS. The clinical outcome assessments and endpoint strategy for the PRIZM study were informed by Tisento's interview study in which individuals living with MELAS described the symptoms and impacts of the disease that are most important to them. Participants who complete treatment in PRIZM have the opportunity to enroll in the open-label extension study. About the PRIZM Study PRIZM – a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS – is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two 12-week treatment periods separated by a 4-week washout period. All participants will receive zagociguat during one of the 12-week periods and placebo during the other. Participants who complete treatment in the study have the opportunity to enroll in an open-label extension study. The global PRIZM study is now enrolling approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. For more information, please visit or (NCT06402123). Interested individuals can also reach out to their physicians for participation details. About Zagociguat Zagociguat is a once-daily, oral, clinical-stage investigational medicine with potential to positively impact both peripheral and central nervous system manifestations of mitochondrial diseases. Zagociguat stimulates soluble guanylate cyclase (sGC), an enzyme that is found in virtually every cell in every tissue of the body and is part of a system of cellular mechanisms that control critical physiological functions including neuronal function and blood flow. A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat may help restore mitochondrial energy production and physiological function. In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function, mitochondrial function, and blood flow in the brain. Zagociguat is currently being evaluated as a treatment for MELAS in the Phase 2b PRIZM study. Zagociguat received Fast Track designation from the U.S. Food and Drug Administration for the treatment of MELAS. Fast Track is a process designed to facilitate the development and potentially expedite the review of medicines to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. For more information, visit About Tisento Therapeutics Tisento Therapeutics, a privately held biotech company, is developing novel medicines to treat diseases with significant unmet need, beginning with MELAS and other genetic mitochondrial diseases. Ti sento means 'I hear you' in Italian; our approach to innovation begins with listening to patients and then channeling what we learn into decisive actions that shape our research and clinical programs. Tisento is guided by a high-caliber internal team of biopharma veterans and an extensive external network of expert physicians, patient advocacy groups, researchers, industry-leading vendors, and other close collaborators who are partners in our mission to develop meaningful treatments for mitochondrial diseases. Learn more at our website, or connect with us on LinkedIn, Facebook, X (@tisentotx), or Bluesky. Contact Tisento Media RelationsJessi Rennekamp, Astrior CommunicationsEmail: jessi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
31 minutes ago
- Medscape
Are UPFs Bad for Weight Loss and Health? It's Complicated
Hardly a day goes by without one or more studies or news stories about ultraprocessed foods (UPFs), most of them negative. The studies often demonize UPFs and urge the public to cut back on them or avoid them entirely. Emerging research suggests a more nuanced approach may be needed. Many researchers warn that UPFs are associated with a higher risk for adverse health outcomes and may even contribute to premature death; however, the 'healthiness' (often undefined in studies) of such foods is not always clearcut. Some studies, as well as a recent advisory from the American Heart Association (AHA), advise cutting back on UPFs with high fat, sugar, and salt content but also acknowledge that certain UPFs can be healthy, are often affordable, and could be part of a high-quality diet. These developments seem to indicate that not all UPFs are the same and that the effect on weight gain and health may be tied to the nutritional value of the food and not just its level of processing. The UPF category is 'so broad it borders on useless,' wrote Nicola Guess, PhD, a registered dietitian at the University of Oxford in Oxford, England, in a recent essay. 'It lumps store-bought whole-grain bread and hummus in with cookies, potato chips, and soda,' she added. Are UPFs an Obesity Culprit? There is general agreement that diets consisting primarily of UPFs are associated with increased energy intake and weight gain, but some experts question whether all UPFs cause people to put on weight. 'Epidemiological and experimental evidence consistently links UPF dietary patterns to increased energy intake, weight gain, and indicators of excess weight,' Filippa Juul of SUNY Downstate Health Sciences University, Brooklyn, New York, and the University of Sao Paulo, Sao Paulo, Brazil, and colleagues wrote in a recent Nature Reviews Endocrinology article. UPFs' negative effects may arise from their 'evolutionarily novel nutritional, physical, and chemical characteristics,' which could influence multiple biological pathways, including food reward systems, appetite and/or satiety regulation, and the microbiome, they added. 'To stem the global rise in obesity, multipronged policy efforts are needed to reduce UPF consumption and create health-promoting food systems,' the researchers concluded. A 2024 evidence review concluded that greater UPF consumption has been a key driver of obesity and that the 'obesogenic environment' must be changed to support efforts to reduce UPF intake. The lead author of that review, Samuel Dicken, PhD, of the Centre for Obesity Research, University College London, London, England, was also the lead author of a recent randomized controlled trial pitting a UPF diet against a minimally processed food (MPF) diet in an 8-week crossover trial. Food in both diets was provided to participants and was nutritionally matched in accordance with the UK's official government advice on how to eat a healthy, balanced diet. The MPF diet was more effective for weight loss than the UPF diet, yielding a 2% average reduction in weight compared with 1% for the UPF diet. Self-reported craving control was also significantly improved with the MPF diet, which may have helped support the lower calorie consumption, the authors suggested. 'Though a 2% reduction may not seem very big, that is only over eight weeks and without people trying to actively reduce their intake,' Dicken said at the time. 'If we scaled these results up over the course of a year, we'd expect to see a 13% weight reduction in men and a 9% reduction in women on the minimally processed diet, but only a 4% weight reduction in men and 5% in women after the ultraprocessed diet. Over time this would start to become a big difference.' However, in comments on the study for the UK's Science Media Centre, several experts pointed out that regardless of the difference in diet, both groups lost weight, calling into question the idea that all UPFs cause weight gain. 'The study suggests that a diet meeting current dietary recommendations is not detrimental to weight maintenance, whether it is ultraprocessed or not,' Gunter Kuhnle, professor of nutrition and food science, University of Reading, Reading, England, noted in his response. In addition, experts noted, the crossover design of the trial, which had both groups following both diets, with a washout period in between, led to an 'order effect,' in which weight loss was less on the second diet across both trial arms. In his response, Kevin McConway, PhD, emeritus professor of applied statistics, The Open University, Milton Keynes, England, took issue with the researchers' methodology for extrapolating the diets' effect over the course of a year and questioned whether the MPF diet would lead to greater weight loss over time. Are All UPFs Unhealthy? If UPFs' effects on weight loss may depend on the foods' quality, could the same be true about the health impacts? Researchers often rely on definitions in the NOVA classification system, which groups foods into four categories ranging from unprocessed/minimally processed to ultraprocessed, in studies evaluating the health effects of UPFs. NOVA warns that the processes and ingredients used to manufacture UPFs typically make them nutritionally unbalanced and liable to be over-consumed and to replace foods that involve less processing. Dietary guidelines, by contrast, focus less on how food is processed and instead emphasize nutritional content, caloric intake, and avoidance of too much added sugar, saturated fat, and salt. Certain foods may be considered healthy by government nutritional standards but not so by NOVA, and vice versa. A recent large study of data from more than 200,000 US adults found that, after adjustment, participants who consumed the most UPFs, as defined by NOVA, were 11% more likely to develop cardiovascular disease (CVD) and 16% more likely to develop coronary heart disease (CHD) during the study period compared with those who consumed the least UPFs. After researchers combined the results with those from 19 other studies, they found that participants who consumed the most UPFs were 17% more likely to develop CVD, 23% more likely to develop CHD, and 9% more likely to have a stroke compared with those who consumed fewest UPFs. But that wasn't the whole story. 'Of note, divergent associations were observed for specific UPF groups in our cohorts,' the authors wrote. 'Sugar-sweetened beverages, processed meats, and artificially sweetened beverages were associated with higher [cardiovascular disease] and [coronary heart disease] risk. Conversely, ultraprocessed savory snacks, cold cereals, and yogurt/dairy-based desserts were inversely associated with CVD and CHD risk. Ultra-processed bread and cold cereals were associated with lower stroke risk, and hard liquors with lower CHD risk.' Similarly, a large study of data from the Nurses' Health Study found that 'high-quality meta-evidence shows that total UPF consumption is associated with higher T2D [type 2 diabetes] risk.' However, the authors wrote, among subgroups of UPFs, 'cereals; dark and whole-grain breads; packaged sweet and savory snacks; fruit-based products; and yogurt and dairy-based desserts were associated with lower T2D risk.' Moreover, in a proof-of-concept study, researchers developed a sample menu that included ≥80% calories from UPFs, as defined by NOVA, yet followed the recommendations for a healthy dietary pattern outlined in the 2020 Dietary Guidelines for Americans. A total of 91% of the calories ended up coming from UPFs, but the menu still scored 86 out of a possible 100 points on the 2015 Healthy Eating Index. 'This sample menu did not achieve a perfect score due primarily to excess sodium and an insufficient amount of whole grains,' the authors wrote. 'This menu provided adequate amounts of all macro- and micro-nutrients, except vitamin D, vitamin E, and choline.' A narrative review poses a key question: Just what might make UPFs bad? Is it the nutrient content or the processing that the food undergoes? The authors concluded that we don't know — which is pretty much the case today. The AHA's scientific advisory and many recent studies call for more research on the health impacts of food additives and processing techniques, as well as research to clarify the impact of UPFs that have better nutrition profiles. In her recent essay, Guess called the focus on UPFs 'a distraction from what we already know about nutrition.…We consume too much fast food, too many sugary beverages, too many cakes, doughnuts and chips. And we consume too few legumes, fruits and vegetables. We need better food and nutrition policies that make it easier for people to purchase and consume a healthier diet.' Dicken reported being funded by the National Institute for Health and Care Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Center, a partnership between the UK NIHR and the UCLH National Health Service Foundation Trust; the Rosetrees Trust; and a UK Medical Research Council grant. Dicken reported receiving royalties from Amazon for a self-published book that mentions UPF, payments from Red Pen Reviews as a contributor, consultancy work for Consensus and Androlabs, and travel fees from a USDA National Institute of Food and Agriculture grant to present a workshop on food processing classifications.
Bloomberg
33 minutes ago
- Bloomberg
Politicizing Scientific Research Comes With a Hefty Price
The Trump administration, seemingly determined to dismantle the National Institutes of Health, continues to devise new and insidious ways to politicize what has long been considered the crown jewel of US research. The latest move? An effort to codify political oversight of the agency's operations and impose abrupt and far-reaching changes to how research funding is allocated. That's left academic researchers — already at the mercy of a mercurial administration — in a constant state of uncertainty, wondering when their work might be targeted next. It's also shrinking the scope of science the NIH is willing to support and making the US a far less attractive place for pursuing biomedical innovation. The long-term consequence? A slowdown in discoveries that could meaningfully improve patients' lives.
